Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Anti-VEGFR2 CAR CD8 lymphocytes |
Trade Name | |
Synonyms | |
Drug Descriptions |
Anti-VEGFR2 CAR CD8 lymphocytes consists of patient's own T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor specific for KDR (VEGFR2), expanded and reintroduced into the patient. The cells bind to and subsequently lyse VEGFR2-expressing cells (NCI Drug Dictionary). |
DrugClasses | VEGFR2 Immune Cell Therapy 1 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Anti-VEGFR2 CAR CD8 lymphocytes | Anti-VEGFR2 CAR CD8 lymphocytes | 0 | 1 |